ENTA
Enanta Pharmaceuticals, Inc.14.85
-0.02-0.13%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
428.61MP/E (TTM)
-Basic EPS (TTM)
-3.84Dividend Yield
0%Recent Filings
10-K
8-K
8-K
Positive zelicapavir Phase 2b results
Enanta Pharmaceuticals announced positive topline results from its Phase 2b RSVHR study of zelicapavir in 186 high-risk adults on September 29, 2025, showing statistically significant 2-day faster symptom resolution by PGI-S and up to 7.2-day faster complete resolution of all RSV symptoms in the HR3 population versus placebo. Zelicapavir also reduced hospitalization rates to 1.7% from 5.0%, achieved a 0.7 log greater viral load decline by day 5, and cleared virus in 23.9% of patients by treatment end. It proved well-tolerated. Data support Phase 3 advancement, yet risks persist in larger trials.
8-K
Positive zelicapavir Phase 2b results
Enanta Pharmaceuticals unveiled positive topline results from its Phase 2b RSVHR study of zelicapavir on September 29, 2025, showing a 6.7-day faster complete resolution of all 13 RSV symptoms in high-risk adults with CHF, COPD, or age over 75, versus placebo. The drug slashed hospitalization rates to 1.7% from 5%, while accelerating undetectable viral load by 4-5 days. Zelicapavir proved safe, with mild adverse events mirroring placebo. This bolsters Phase 3 designs, yet development risks loom large.
8-K
Interim finance leadership appointed
Enanta Pharmaceuticals appointed Harry R. Trout III as interim principal financial officer and Kathleen S. Capps as interim principal accounting officer on August 26, 2025, while CFO Paul J. Mellett takes medical leave. Both executives bring deep internal experience—Trout since 2002 in finance roles, Capps since 2016 in accounting. No new compensation arrangements were disclosed. This temporary shift ensures continuity in financial oversight amid the absence.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ASMB
Assembly Biosciences, Inc.
33.50-1.10
AVIR
Atea Pharmaceuticals, Inc.
3.22+0.07
COCP
Cocrystal Pharma, Inc.
0.98-0.04
HEPA
Hepion Pharmaceuticals, Inc.
0.07-0.01
HOOK
HOOKIPA Pharma Inc.
0.87-0.02
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
NNVC
NanoViricides, Inc.
1.29+0.06
TRDA
Entrada Therapeutics, Inc.
11.37+0.34
VIR
Vir Biotechnology, Inc.
6.48-0.24